Jhoti H, et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol. (2007) 11:485-493
In the same vein is a paper from Teddy Zartler at Merck that also discusses the concept of ligand efficiency in FBDD:
Zartler ER and MJ Shapiro. Fragonomics: fragment-based drug discovery. Curr Opin Chem Biol. (2005) 9:366-370
Tethering, an alternate approach to FBDD pioneered by Sunesis Pharmaceuticals, is discussed in this review:
Erlanson DA and SK Hansen. Making drugs on proteins: site-directed ligand discovery for fragment based assembly. Curr Opin Chem Biol. (2004) 8:399-406.